Prime Medicine, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-09: Study NCT07748403; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Recruiting.
- 2025-12-29: Study NCT07226622; Company role Lead sponsor; Phase Observational; Status Active not recruiting.
- 2024-10-17: Study NCT06559176; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Enrolling by invitation.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-09 | NCT07748403 A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) | Lead sponsor | Phase 1, Phase 2 | Recruiting | Wilson Disease; Wilson's Disease; Wilsons Disease | 42 | 2028-12 |
| 2025-12-29 | NCT07226622 Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial | Lead sponsor | Observational | Active not recruiting | Wilson Disease | 30 | 2027-12 |
| 2024-10-17 | NCT06559176 A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) | Lead sponsor | Phase 1, Phase 2 | Enrolling by invitation | Chronic Granulomatous Disease; Granulomatous Disease, Chronic | 12 | 2030-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |